Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
Mylan Adds to Central Nervous System Portfolio With Launch of Generic Exelon(R) Patch
HERTFORDSHIRE, England and PITTSBURGH, July 9, 2018 -- (Healthcare Sales & Marketing Network) -- Mylan N.
Results of Phase III (PIX306) Trial Evaluating Progression-Free Survival of PIXUVRI(R) (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma
SEATTLE, July 9, 2018 -- (Healthcare Sales & Marketing Network) -- CTI BioPharma Corp.
Orion has started a Phase III trial to develop a drug for ALS - The patient recruitment has begun
ESPOO, Finlandn I July 6, 2018 I Orion has recruited the first patients in the Phase III clinical trial (REFALS) in which orally administered levosimendan (ODM-109) is being evaluated ...
CTI Biopharma's cancer drug fails late-stage trial, shares tumble
(Reuters) - CTI Biopharma Corp said on Monday its treatment for a type of blood cancer did not meet the main goal of a late-stage trial, sending its shares down 17 percent.
Species-specific activity of antibacterial drug combinations
The spread of antimicrobial resistance has become a serious public health concern, making once-treatable diseases deadly again and undermining the achievements of modern medicine.
Bristol-Myers Squibb looks to sell French OTC unit which could bring $1.8B: report
Add Bristol-Myers Squibb to the list of Big Pharmas doing consumer health reevaluations these days.
Alzheimer's: Aspirin may reduce toxic plaque
A new study published in the Journal of Neuroscience suggests that regular intake of low-dose aspirin may prevent Alzheimer's pathology from forming in the brain and protect the memory of those li...
Study reveals potential approach to treat dementia, stroke
WASHINGTON, July 4 (Xinhua) -- A study published on Wednesday in the journal Science Translational Medicine revealed a potential approach to treat one of the commonest causes of dementia and s...
Biogen, Eisai's Alzheimer's drug succeeds in mid-stage trial, shares soar
(Reuters) - Japanese drugmaker Eisai Co and Biogen Inc said that the final analysis of a mid-stage trial of their Alzheimer’s drug showed positive results for patients who received the highe...
Alkermes Receives $50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development Program
DUBLIN, June 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq.
This new diabetes drug can help reverse a fatal lung disorder
Pulmonary fibrosis can develop after lung injuries like infections, radiation or chemotherapy, or it can have an unknown cause, as in idiopathic pulmonary fibrosis, or IPF.
Ex-Millennium chief Deborah Dunsire looks for pipeline growth as Lundbeck's CEO
Neuroscience specialist Lundbeck has been running without a permanent CEO since last November when then-helmsman Kåre Schultz left for Teva’s top job.
430
431
432
433
434
435
436
437
438
